<?xml version='1.0' encoding='iso-8859-1'?>
<newsitem date="1997-08-04" id="root" itemid="775935" xml:lang="en">
<title>USA: Enzon gets $2.5 mln in milestone payments.</title>
<headline>Enzon gets $2.5 mln in milestone payments.</headline>
<dateline>PISCATAWAY, N.J. 1997-08-04</dateline>
<text>
<p>Enzon Inc said Monday Schering-Plough Corp advanced the company's anti-cancer agent PEG-INTRON A to Phase III clinical trials in the U.S. and Europe, entitling Enzon to $2.5 million in milestone payments.</p>
<p>Enzon said it and Schering-Plough have a licensing agreement for the ani-cancer and anti-viral agentt, which is a longer-acting form of Schering-Plough's INTRON A. The deal entitles Enzon to $5.5 million in milestone payments, of which it now receives $2.5 million.</p>
</text>
<copyright>(c) Reuters Limited 1997</copyright>
<metadata>
<dc element="dc.date.created" value="1997-08-04" />
<dc element="dc.publisher" value="Reuters Holdings Plc" />
<dc element="dc.date.published" value="1997-08-04" />
<dc element="dc.source" value="Reuters" />
<dc element="dc.creator.location" value="PISCATAWAY, N.J." />
<dc element="dc.creator.location.country.name" value="USA" />
<dc element="dc.source" value="Reuters" />
</metadata>
</newsitem>